CELLforCURE (SEQENS)
Les Ulis, FR
Program data pending ClinicalTrials.gov matching
· Last scored 2026-03-15
63.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
○ Press
Quick Facts: CELLforCURE (SEQENS)
- Signal Score
- 63.0/100 (as of 2026-03-15)
- Quality Compliance
- Assessment pending
- Headquarters
- Les Ulis, FR
- Modalities
- CAR-T, Cell Therapy
- Active CGT Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CGT manufacturing intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
68.0
Parent company: SEQENS
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Subsidiary of SEQENS
SEC FilingsParent: SEQENS
Parent company: SEQENS
Financial assessment: 68.0/100
Capacity
58.0
1 CGT manufacturing site: Les Ulis, France
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Sites: Les Ulis, France
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
1 CGT manufacturing site: Les Ulis, France
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: